Journal of Yeungnam Medical Science

Yeungnam University College of Medicine, Yeungnam University Institute Medical Science (영남대 의대 학술지 편집위원회)
권호 표지
DOI QR코드

DOI QR Code

Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor

  • Kang, Min Kyu (Department of Internal Medicine, Yeungnam University College of Medicine) ;
  • Lee, Heon Ju (Department of Internal Medicine, Yeungnam University College of Medicine) ;
  • Choi, Joon Hyuk (Department of Pathology, Yeungnam University College of Medicine)
  • Received : 2018.12.04
  • Accepted : 2019.01.16
  • Published : 2019.05.31
Download PDF
⟨ Previous Next ⟩

Abstract

Imatinib mesylate is currently used as the first-line treatment for metastatic gastrointestinal stromal tumors (GISTs). Imatinib-induced hepatotoxicity in patients with GIST is very rare. Its features vary from subclinical elevation of serum aminotransferase to clinically apparent acute hepatitis, which is associated with immunologic reactions. Imatinib-induced hepatotoxicity with autoimmune-like features can be treated by the discontinuation of imatinib mesylate and the administration of oral steroids. Here, we report a case of late-onset imatinib-induced hepatitis with autoimmune-like features in a patient with metastatic GIST, which was improved by oral corticosteroids.

Keywords

References

  1. Pariente A, Etcharry F, Cales V, Laborde Y, Ferrari S, Biour M. Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour. Eur J Gastroenterol Hepatol 2006;18:785-7. https://doi.org/10.1097/01.meg.0000216941.42306.0e
  2. Tonyali O, Coskun U, Yildiz R, Karakan T, Demirci U, Akyurek N, et al. Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors. Med Oncol 2010;27:768-73. https://doi.org/10.1007/s12032-009-9284-y
  3. Seidel C, Fenner M, Langer F, Bantel H, Ganser A, Grunwald V. Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST). BMC Cancer 2012;12:186. https://doi.org/10.1186/1471-2407-12-186
  4. Yachoui R. Early onset imatinib mesylate-induced hepatotoxicity in a patient with gastrointestinal stromal tumors. Am J Ther 2014;21:e148-50. https://doi.org/10.1097/MJT.0b013e31826fc5d1
  5. Ferrero D, Pogliani EM, Rege-Cambrin G, Fava C, Mattioli G, Dellacasa C, et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica 2006;91(6 Suppl): ECR27.
  6. Al Sobhi E, Zahrani Z, Zevallos E, Zuraiki A. Imatinib-induced immune hepatitis: case report and literature review. Hematology 2007;12:49-53. https://doi.org/10.1080/10245330600937929
  7. Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist 2004;9:271-81. https://doi.org/10.1634/theoncologist.9-3-271
  8. Sharma A, Houshyar R, Bhosale P, Choi JI, Gulati R, Lall C. Chemotherapy induced liver abnormalities: an imaging perspective. Clin Mol Hepatol 2014;20:317-26. https://doi.org/10.3350/cmh.2014.20.3.317
  9. Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev 2011;37:75-88. https://doi.org/10.1016/j.ctrv.2010.04.008
  10. Almazroo OA, Miah MK, Venkataramanan R. Drug Metabolism in the Liver. Clin Liver Dis 2017;21:1-20. https://doi.org/10.1016/j.cld.2016.08.001
  11. Doring B, Petzinger E. Phase 0 and phase III transport in various organs: combined concept of phases in xenobiotic transport and metabolism. Drug Metab Rev 2014;46:261-82. https://doi.org/10.3109/03602532.2014.882353
  12. Willson TM, Kliewer SA. PXR, CAR and drug metabolism. Nat Rev Drug Discov 2002;1:259-66. https://doi.org/10.1038/nrd753
  13. Hunt CM, Papay JI, Stanulovic V, Regev A. Drug rechallenge following drug-induced liver injury. Hepatology 2017;66:646-54. https://doi.org/10.1002/hep.29152
  14. Saif MW, Smith MH, Maloney A, Diasio RB. Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor. Ann Gastroenterol 2016;29:551-6.